Kaposi's sarcoma
"Prospective Randomized Trial of Two Dose Levels of Interferon alfa With Zidovudine for the Treatment of Kaposi's Sarcoma Associated With Human Immunodeficiency Virus Infection: A Canadian HIV Clinical Trials Network St
Published in AIDS Weekly, June 22nd, 1998
According to the authors' abstract of an article published in Journal of Clinical Oncology, "Purpose: Interferon alfa alone has shown antitumor activity against Kaposi's sarcoma (KS), and Phase I and II clinical trials showed that interferon and zidovudine could be administered safely to patients with human immunodeficiency virus (HIV)-associated KS. These observations led to our trial of zidovudine with two dose levels of interferon alfa. Methods: HIV positive patients with KS were eligible if they were older than 18 years of age, had a performance status of 0 to 2, and were free of active infection. All patients received zidovudine 500 mg daily and were randomized to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1998-06-22)
More Articles from AIDS Weekly
- Conference Coverage (World AIDS Conference)
Overview of 12th World AIDS Conference - AIDS Pathogenesis
Ho's "Raging Fire" Put Out - AIDS Therapies
FDA Fast-Tracks DuPont Merck's Efavirenz - AIDS Vaccines
Controversial Phase III Trials Get FDA Nod - Conference Coverage (World AIDS Conference)
Meet the Experts, Live from Geneva - AIDS Therapies
HAART Effect on Immune Response Studied - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
